ArticleRadiation oncology (London, England)2026
Patterns of care and outcome of liver SBRT: results from a multicentre National quality project.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStereotactic body radiotherapy (SBRT) is applied for both primary liver tumours and liver metastases. Within a national project, we investigated patterns of care for liver SBRT and factors influencing local control (LC) and overall survival (OS).
methodsPatients treated with SBRT were prospectively registered within a quality assurance project. Patient- and tumour-related factors, and data on use of markers, personalised immobilisation, image guidance and radiotherapy techniques were collected. OS and LC were evaluated by Kaplan-Meier analysis and Cox proportional hazard models.
resultsFrom August 2013 to December 2019, fourteen centres treated 352 patients with SBRT for a total of 408 lesions (66 primary, 342 metastases). Colorectal adenocarcinoma was the most common primary cancer (n = 170, 42%). A gradual uptake of SBRT and increasing prescription dose were observed over time. One, 2- and 5- year OS probabilities were 74.3%, 49.7% and 19.4%. LC data were available for 354 lesions. LC probabilities at 1-, 2- and 5-years were 69.9%, 52.2% and 32.4%. Better OS and LC were found for patients with smaller PTV volumes and higher BED10. Patients with better performance status had a better OS. A better LC was observed in patients who were not priorly treated with systemic therapy.
conclusionsWe observed an increase in liver SBRT uptake and a reasonable LC and OS. Higher BED10 and smaller PTV volumes translated into high local tumour control and survival. After correction of patient case-mix, none of the technical parameters showed a significant association with outcome.
trial registrationNot applicable, this is a retrospective analysis of data that were prospectively registered as part of a national quality assurance programme of the Belgian Cancer Registry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.